Infiltration of CD4, CD8, CD56, and Fox-P3-positive lymphocytes in breast carcinoma tissue after neoadjuvant chemotherapy with or without trastuzumab
[Breast Disease, 38(2) 2019, 57–65, DOI 10.3233/BD-180350]
https://content.iospress.com/articles/breast-disease/bd180350
On page 61, Table 2, in the Tz+ group, the average number of immunoreactive CD8 cells in the intratumoral (I) compartment, previously reported as 17.3, has now been revised as 1.73.
On page 62, in Table 2 (continued), within the CD8/Fox-P3 column, the absence of Fox-P3-positive cells, previously reported as “0”, has now been revised as “−”. In addition, in the Tz+ group, in case 6, the number of CD8/Fox-P3-positive cells in the adjacent (A) and distal (D) stromal compartments, previously reported as 1.2 and 6.8, respectively, has now been revised as 6.8 and 1.1, respectively. In the Tz− group, in case 13, the number of CD8/Fox-P3-positive cells in the D compartment, previously reported as 1, has now been revised as 6.6. In the Tz+ group, the average CD8/Fox-P3-positive cells in the I, A, and D compartments, previously reported as 0.3, 6.2, and 5.3, respectively, has been revised as 3, 11, and 10.6, respectively. In the Tz− group, the average CD8/Fox-P3-positive cells in the A and D compartment, previously reported as 4 and 1.3, respectively, has now been revised as 30.5 and 12.6, respectively.
On page 63, CD4 and CD8 in graph [b] and Fox-P3 and in graph [b and c] of Figure 2 have been revised. Furthermore, the statistical test mentioned at the lower right end of Figure 2, previously reported as Welch’s t-test, has now been revised as Mann–Whitney U test.
The revised Table 2 (Tz+ and Tz− group, CD8 and CD8/Fox-P3) is shown below:
Table 2
Expression of CD8 and CD8/Fox-P3-positive cells in each compartment
| Tz+ group | CD8 | CD8/Fox-P3 | ||||
| Case | I | A | D | I | A | D |
| 1 | 3.4 | 39.2 | 63.6 | – | – | – |
| 2 | 0.6 | 86.4 | 23.2 | – | – | – |
| 3 | 2.8 | 24.6 | 18 | – | – | – |
| 4 | 1.2 | 1.8 | 10.8 | – | – | – |
| 5 | 0.4 | 1.4 | 20.8 | – | – | – |
| 6 | 0.2 | 64 | 9.4 | – | 6.8 | 1.1 |
| 7 | 0.2 | 3 | 0.6 | 1 | 0.4 | – |
| 8 | 2.2 | 39.8 | 12 | 5.5 | 1 | 0.8 |
| 9 | 0 | 37 | 10.2 | – | – | – |
| 10 | 2 | 53.8 | 15.2 | 2.5 | 13.5 | 12.7 |
| 11 | 2 | 106 | 21.8 | – | 15.1 | 36.3 |
| 12 | 7.2 | 230.6 | 5 | – | 21 | 3.1 |
| 13 | 1.2 | 19.8 | 13.8 | – | 4 | 11.5 |
| 14 | 0 | 19.8 | 1.8 | – | 7.1 | 9 |
| 15 | 2.6 | 53.6 | 11 | – | 29.8 | – |
| Average | 1.73 | 52 | 15.8 | 3 | 11 | 10.6 |
| Tz− group | CD8 | CD8/Fox-P3 | ||||
| Case | I | A | D | I | A | D |
| 1 | 1.4 | 34 | 9.8 | – | – | – |
| 2 | 0.2 | 3.6 | 12.2 | – | – | – |
| 3 | 0.2 | 15.2 | 16.4 | – | – | – |
| 4 | 0.6 | 13.2 | 2.6 | – | – | – |
| 5 | 2.6 | 12.4 | 10.4 | – | – | – |
| 6 | 0.2 | 0.8 | 2.4 | – | – | – |
| 7 | 0.4 | 7.6 | 0.4 | – | – | – |
| 8 | 0.4 | 9.2 | 0.4 | – | 46 | – |
| 9 | 0 | 6.6 | 7.4 | – | – | 18.5 |
| 10 | 1.2 | 20.2 | 11.4 | – | – | – |
| 11 | 1.2 | 10.2 | 8.2 | – | – | – |
| 12 | 0 | 0.2 | 0.2 | – | – | – |
| 13 | 0.6 | 3 | 10.6 | – | 15 | 6.6 |
| 14 | 1.2 | 18.6 | 11.8 | – | – | – |
| Average | 0.7 | 11.1 | 7.4 | – | 30.5 | 12.6 |
[i] A, adjacent stromal compartment; D, distal stromal compartment; I, intratumoral compartment; Tz, Trastuzumab; –, Fox-P3-positive cells were not found.
The revised Fig. 2 is shown below:
Fig. 2.
Number of CD4-, CD8-, and Fox-P3-positive cells in the three different tissue compartments, (a) adjacent lesion, (b) distant lesion, and (c) intratumor lesion, with or without trastuzumab therapy.
